Prescription Medicine

Respiratory

Boehringer Ingelheim has over 90 years of heritage in respiratory disease. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer. Our focus is on improving the quality of life of patients suffering from debilitating respiratory diseases and enabling them to maintain a more independent life.

 


Bronchial asthma is a chronic inflammatory disorder of the airways. Patients suffer from wheezing, breathlessness and coughing particularly at night or in the early hours of the morning. This can affect the patient’s physical, social and professional lives significantly. Asthma is often seen as an easy to manage condition but it is known that 1 in 2 asthma patients still have symptoms despite current treatment. An exacerbation of asthma, which is more commonly called an asthma attack, can be triggered by factors such as respiratory infections, environmental and atmospheric conditions.

Information for
General Information Patients & Carers Health Care Professional in the US Health Care Professional outside the US Journalists Jobseekers